A Study of LY3502970 in Participants With Type 2 Diabetes Mellitus
Type 2 Diabetes

About this trial
This is an interventional treatment trial for Type 2 Diabetes
Eligibility Criteria
Inclusion Criteria:
- Have been diagnosed with Type 2 Diabetes on diet and exercise and/or a stable dose of metformin
- Have a stable body weight for the 3 months prior to randomization
- Have a body mass index (BMI) ≥23 kilogram/square meter (kg/m²)
- Males must agree to use highly effective methods of contraception
- Women not of childbearing potential (WNOCBP) may participate in this trial
- Note: Hormone replacement therapy in post-menopausal women is allowed but women must be on stable therapy for 3 months prior to day 1.
Exclusion Criteria:
- Have Type 1 diabetes mellitus (T1DM) or history of ketoacidosis or hyperosmolar coma
- Have a history of diabetic retinopathy, diabetic maculopathy, or severe non-proliferative diabetic retinopathy that requires immediate treatment intervention
- Have had more than 1 episode of severe hypoglycemia and aware of hypoglycemic symptoms
- Have acute or chronic pancreatitis
- Have obesity induced other endocrine disorders (Cushing's syndrome or Prader - Willi syndrome)
- Have gastric emptying abnormality or chronically take medications impacting GI motility
- Have poorly controlled hypertension
- Have the following heart conditions within the last 6 months: myocardial infarction (MI), unstable angina, coronary artery bypass graft, percutaneous coronary intervention (diagnostic angiograms are permitted), transient ischemic attack (TIA), cerebrovascular accident (stroke)or decompensated congestive heart failure, or IV heart failure
- Have any symptoms of other liver diseases besides nonalcoholic fatty liver disease (NAFLD)
- Have HIV, or Hepatitis B or Hepatitis C
Sites / Locations
- Anaheim Clinical Trials, LLC
- Velocity Clinical Research, Huntington Park
- Velocity Clinical Research, Westlake
- Rancho Cucamonga Clinical Research
- Touro University California
- New West Physicians Clinical Research
- Optumcare Colorado Springs - Monument
- Cotton O'Neil Clinical Research Center
- Clinvest Research LLC
- Premier Research
- Intend Research, LLC
- Capital Area Research, LLC
- Family Medical Associates
- Tristar Clinical Investigations
- Dallas Diabetes Research Center
- Biopharma Informatic, LLC
- Bandera Family Health Care
- Consano Clinical Research, LLC
- Capital Clinical Research Center
- Eastside Research Associates
- Bugát Pál Kórház
- Kanizsai Dorottya Korhaz
- Zala Megyei Szent Rafael Kórház
- Szent Margit Rendelőintézet Nonprofit Kft
- Clinexpert Kft.
- ClinDiab Kft.
- TRANTOR'99 Bt. Anyagcsere Centrum
- Strazsahegy Medicina Bt.
- Wojewódzki Zespól Specjalistycznej Opieki Zdrowotnej
- Gabinety TERPA
- NZOZ Medica
- Centralny Szpital Kliniczny MSWiA w Warszawie
- Centrum Zdrowia Tuchów
- Centrum Badan Klinicznych PI-House sp. z o.o.
- Centrum Terapii Wspolczesnej J. M. Jasnorzewska Spolka Komandytowo-Akcyjna
- NZOZ Przychodnia Specjalistyczna Andrzej Wittek, Henryk Rudzki
- Dorado Medical Complex
- Clinical Research Management Group Inc. - Hospital San Cristobal
- BRCR Global Puerto Rico-Unda
- Ambulancia diabetológie a porúch látkovej premeny a výživy - DIABEDA
- Diabetol
- MEDI-DIA s.r.o.
- DIA-MED CENTRUM s.r.o.
- Funkystuff
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Arm 6
Arm 7
Arm 8
Arm 9
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
Active Comparator
Placebo Comparator
3 milligrams (mg) LY3502970
12 mg LY3502970
24 mg LY3502970
36 mg LY3502970 - 1
36 mg LY3502970 - 2
45 mg LY3502970 - 1
45 mg LY3502970 - 2
1.5 mg Dulaglutide
Placebo
Participants received maintenance dose of 3 mg with dose escalation starting from 2 mg LY3502970 administered orally once daily (QD).
Participants received maintenance dose 12 mg with dose escalation starting from 2 mg, 6 mg and then 12 mg LY3502970 administered orally QD.
Participants received maintenance dose 24 mg with dose escalation starting from 3 mg, 6 mg, 8 mg,12 mg and then 24 mg LY3502970 administered orally QD.
Participants received maintenance dose 36 mg with dose escalation starting from 2 mg, 3 mg, 6 mg, 8 mg, 12 mg, 24 mg and then 36 mg LY3502970 administered orally QD.
Participants received maintenance dose 36 mg with dose escalation starting from 3 mg, 6 mg,12 mg, 24 mg and then 36 mg LY3502970 administered orally QD.
Participants received maintenance dose 45 mg with dose escalation starting from 3 mg, 6 mg, 8 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 administered orally QD.
Participants received maintenance dose 45 mg with dose escalation starting from 2 mg, 3 mg, 6 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 administered orally QD.
Participants received 1.5 mg Dulaglutide administered subcutaneously (SC) once weekly (QW).
Participants received matching placebo.